updat endometriosi
phase edelweiss data mid-year clarifi
endometriosi competit profil earn
unev timelin remain track phase readout
primari endpoint studi endometriosi associ
pelvic pain score week bmd readout also
get addit clariti stand-alon vs addback dose compani
fda previous commun pain reduct would meet
efficaci threshold multipl potenti player market
abbvie/neurocrin myovant believ bar higher
commerci relev abbvie/neurocrin show
pain reduct placebo elagolix elagolix
group respect phase studi kissei show reduct
point scale treatment group vs
point reduct placebo group think key comparison
read seen myovant studi
endometriosi catalyst remain primari endpoint
data mid-year bone miner densiti week pain data
data pre-term labor late year
ep
previous risk outperform rate target price includ
clinic failur delay lower expect sale
nolasiban greater expect competit
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
obseva clinical-stag biopharmaceut compani focus
develop commerci novel therapeut
seriou condit compromis woman reproduct health
pregnanc
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario assum po
endometriosi po uterin fibroid po
nolasiban ivf
grey sky scenario repres stock trade cash
 close
think bone miner densiti data may bigger driver
stock although primari efficaci endpoint readout think
data edelweiss provid key competit inform equival data
superior dose profil still feel confid abil compet
endometriosi uterin fibroid market think data must par
mid-year pdufa date enter market year
behind endometriosi year behind uf think obseva still
signific player market begin build think
efficaci safeti data respect bmd must equival obseva
enter market convenience/dos edg model success
uf endometriosi launch peak sale respect
nolasiban regulatori updat inform time eu commerci
pathway addit us trial posit nolasiban data last month
compani expect take data fda mid-year ema septemb
time-frame minut fda meet receiv would expect hear
detail addit us clinic requir eu side
expect find data suitabl registr whether anoth trial
need current model po eu launch us launch
peak sale respect also see poc data
prolong pre-term later late year program remain upsid
valuat
compani mention price
